Thrombocytopenia: ITP, TTP, HIT, and Platelet Transfusion Thresholds

Thrombocytopenia is defined as a platelet count <150,000/μL, with severe thrombocytopenia occurring at <50,000/μL and life-threatening levels at <10,000/μL. [KEY_CONCEPT] The four major causes requiring immediate recognition are immune thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), heparin-induced thrombocytopenia (HIT), and conditions requiring platelet transfusion.

Immune Thrombocytopenic Purpura (ITP) is an autoimmune disorder with antibodies against platelet surface glycoproteins, particularly GPIIb/IIIa and GPIb/IX. Primary ITP has an incidence of 3-4 per 100,000 adults annually, with a female predominance (3:1 ratio). Secondary ITP occurs with systemic lupus erythematosus, chronic lymphocytic leukemia, hepatitis C, and HIV.

Thrombotic Thrombocytopenic Purpura (TTP) is a rare thrombotic microangiopathy with an incidence of 3-11 cases per million annually. It results from severe deficiency (<10%) of ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13), either acquired (autoantibodies) or congenital.

Heparin-Induced Thrombocytopenia (HIT) occurs in 1-3% of patients receiving unfractionated heparin and 0.1-1% with low molecular weight heparin. [HIGH_YIELD] Type II HIT involves antibodies against the heparin-platelet factor 4 complex, causing paradoxical thrombosis despite thrombocytopenia.

[CLINICAL_PEARL] The "4 T's" scoring system (Thrombocytopenia severity, Timing of onset, Thrombosis, and other causes) helps assess HIT probability, with scores ≥6 indicating high probability.

The clinical presentation varies significantly based on the underlying etiology:

ITP Clinical Features:

• Mucocutaneous bleeding: petechiae, purpura, epistaxis, menorrhagia
• Wet purpura (mucosal bleeding) indicates higher bleeding risk
• Absence of splenomegaly (distinguishes from other causes)
• No constitutional symptoms or lymphadenopathy

TTP Pentad (classic but rare - only 5% have all features):

1. Thrombocytopenia
2. Microangiopathic hemolytic anemia (MAHA)
3. Neurologic symptoms (confusion, seizures, stroke)
4. Renal dysfunction
5. Fever

[HIGH_YIELD] Modern diagnosis requires only thrombocytopenia + MAHA, as waiting for the full pentad delays life-saving treatment.

HIT Clinical Features:

• Thrombocytopenia typically 5-10 days after heparin initiation
• Paradoxical thrombosis: venous > arterial
• Skin necrosis at heparin injection sites
• Adrenal hemorrhage (rare but pathognomonic)

[CLINICAL_PEARL] In hospitalized patients with thrombocytopenia, always review medication history for heparin exposure, including heparin flushes and line coatings.

Initial Laboratory Assessment:

Complete Blood Count with Peripheral Smear ↓ Comprehensive Metabolic Panel ↓ LDH, Haptoglobin, Indirect Bilirubin ↓ Direct Coombs Test ↓ Coagulation Studies (PT/INR, aPTT)

ITP Diagnostic Criteria (ASH Guidelines):

• Isolated thrombocytopenia (<100,000/μL)
• Normal or increased megakaryocytes on bone marrow (if performed)
• Exclusion of other causes of thrombocytopenia
• No splenomegaly on examination
• Normal white blood cell and red blood cell counts

TTP Diagnostic Workup:

• ADAMTS13 activity <10% (confirmatory but don't wait for results)
• ADAMTS13 inhibitor (acquired) vs genetic testing (congenital)
• [KEY_CONCEPT] Peripheral smear showing schistocytes is crucial
• Elevated LDH (>2x upper limit normal)
• Decreased haptoglobin
• Negative direct Coombs test

HIT Diagnostic Algorithm:

Clinical suspicion (4T score ≥4) ↓ Immediate heparin discontinuation ↓ HIT antibody testing:

• Immunoassay (PF4/heparin ELISA) - high sensitivity
• Functional assay (SRA) - high specificity ↓ High probability: Start alternative anticoagulation Low probability: Consider other causes

4T Scoring System:

• Thrombocytopenia: >50% decrease (2 points), 30-50% (1 point), <30% (0 points)
• Timing: 5-10 days or ≤1 day with recent exposure (2 points)
• Thrombosis: New thrombosis (2 points), progressive/recurrent (1 point)
• Other causes: None evident (2 points), possible (1 point), definite (0 points)

[HIGH_YIELD] Score interpretation: 0-3 (low), 4-5 (intermediate), 6-8 (high probability)

ITP Management Algorithm:

Platelet count assessment ↓

30K + no bleeding → Observation ↓ <30K or bleeding → First-line therapy:

• Corticosteroids (prednisolone 1mg/kg/day)
• IVIG (1g/kg × 1-2 days) for rapid response
• Anti-D (if Rh+, spleen intact) ↓ Refractory/Relapsed → Second-line:
• Rituximab, TPO agonists (romiplostim, eltrombopag)
• Splenectomy (if age >18, vaccinated) ↓ Emergency (severe bleeding) → Emergency measures:
• High-dose steroids + IVIG
• Platelet transfusion
• Consider splenectomy

TTP Management (URGENT):

1. Immediate plasma exchange (within 4-8 hours of diagnosis)
   • Remove ADAMTS13 autoantibodies
   • Replace functional ADAMTS13
   • Continue until platelet count >150K for 2 consecutive days
2. Corticosteroids (methylprednisolone 1mg/kg/day)
3. Rituximab for refractory cases or relapse prevention
4. [CLINICAL_PEARL] Avoid platelet transfusion unless life-threatening bleeding (may worsen thrombosis)

HIT Management:

1. Immediate heparin discontinuation (all forms including flushes)
2. Alternative anticoagulation (even without thrombosis):
   • Argatroban (direct thrombin inhibitor) - preferred if renal dysfunction
   • Bivalirudin (shorter half-life)
   • Fondaparinux (if normal renal function)
3. Warfarin transition only after platelet recovery (>150K)
4. [HIGH_YIELD] Never use warfarin alone initially (increased thrombosis risk)

Platelet Transfusion Thresholds:

| Clinical Scenario | Threshold | |------| | Active bleeding | <50,000/μL | | Major surgery/procedure | <50,000/μL | | CNS bleeding risk | <100,000/μL | | Prophylactic (stable) | <10,000/μL | | Prophylactic (fever/bleeding risk) | <20,000/μL |

[KEY_CONCEPT] One unit of platelets increases count by 5,000-10,000/μL in average adult.

ITP Complications:

• Intracranial hemorrhage (<1% but most serious complication)
• Chronic ITP (>12 months duration) - affects 20-30% of adults
• Secondary causes: Must exclude SLE, CLL, hepatitis C, H. pylori
• Treatment-related: Corticosteroid side effects, infection risk with immunosuppression

[HIGH_YIELD] Splenectomy considerations: Vaccinate against encapsulated organisms (pneumococcus, meningococcus, H. influenzae) 2-3 weeks before surgery.

TTP Complications:

• Mortality: 90% without treatment, <10% with prompt plasma exchange
• Neurologic sequelae: Cognitive impairment, seizure disorder (30% of survivors)
• Relapse: 30-50% risk, typically within 30 days
• Refractory TTP: <50% platelet count response after 7 days of plasma exchange

TTP Monitoring Protocol:

• Daily CBC, LDH, neurologic assessment
• ADAMTS13 activity (goal >10% with undetectable inhibitor)
• [CLINICAL_PEARL] Platelet count recovery precedes LDH normalization

HIT Complications:

• Thrombosis: Occurs in 30-50% of HIT patients
  • Venous: DVT, PE, cerebral sinus thrombosis
  • Arterial: MI, stroke, limb ischemia
• Delayed-onset HIT: Can occur up to 3 weeks after heparin discontinuation
• Persisting antibodies: Can persist for months (affects future heparin use)

Monitoring Parameters:

| Condition | Key Monitoring | Frequency | |------| | ITP | CBC, bleeding assessment | Weekly initially, then monthly | | TTP | CBC, LDH, neurologic exam | Daily during treatment | | HIT | Platelet count, thrombosis screening | Daily until recovery |

Long-term Management Considerations:

• ITP: Annual CBC, consider bone density monitoring if chronic steroids
• TTP: ADAMTS13 monitoring, relapse surveillance
• HIT: Document allergy, consider alternative anticoagulation strategies

[KEY_CONCEPT] Refractory cases may require second-line agents: TPO receptor agonists for ITP, rituximab for TTP, or plasma filtration techniques.

ITP Prognosis:

• Acute ITP (children): 80% spontaneous remission within 6 months
• Chronic ITP (adults): <20% spontaneous remission
• Response to first-line therapy: 70-80% initial response rate
• Long-term outcomes: Most patients achieve sustained response with appropriate treatment

[HIGH_YIELD] Pregnancy considerations: ITP may worsen during pregnancy; maternal antibodies can cross placenta causing neonatal thrombocytopenia.

TTP Prognosis:

• Acute mortality: Reduced from 90% to <10% with plasma exchange
• Relapse rate: 30-50%, usually within 30 days of initial episode
• Long-term survival: >90% at 5 years with appropriate treatment
• Neurologic recovery: Most patients recover completely, but 30% have residual deficits

HIT Prognosis:

• Thrombosis risk: 30-50% develop thrombotic complications
• Resolution: Platelets typically recover within 4-14 days after heparin discontinuation
• Antibody persistence: HIT antibodies decline over 50-100 days
• Future heparin exposure: May be possible after antibody clearance (>100 days)

Prevention Strategies:

ITP Prevention:

• Avoid unnecessary medications that can cause thrombocytopenia
• Vaccination status optimization before immunosuppressive therapy
• Regular monitoring in patients with secondary causes

TTP Prevention:

• Rituximab prophylaxis may reduce relapse risk in high-risk patients
• Avoid triggering factors: certain medications (ticlopidine, clopidogrel), pregnancy complications
• Family screening for congenital TTP (ADAMTS13 mutations)

HIT Prevention:

• Limit heparin duration when possible
• Prefer low molecular weight heparin over unfractionated heparin
• Use alternative anticoagulants in high-risk patients
• [CLINICAL_PEARL] Mechanical prophylaxis preferred in patients with previous HIT

Monitoring Guidelines:

• ITP: CBC every 3-6 months in stable chronic disease
• TTP: ADAMTS13 activity monitoring in remission
• HIT: Platelet monitoring for 14 days in high-risk patients receiving heparin

Patient Education:

• Bleeding precautions and when to seek emergency care
• Medication compliance importance
• Recognition of relapse symptoms
• Dental care modifications during active disease